Integra LifeSciences Holdings
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Integra LifeSciences Holdings's revenues will expand 6.1% and EPS will grow 5.6%.
The average estimate for revenue is $215.9 million. On the bottom line, the average EPS estimate is $0.76.
Last quarter, Integra LifeSciences Holdings chalked up revenue of $210.1 million. GAAP reported sales were 3.9% higher than the prior-year quarter's $202.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.85. GAAP EPS of $0.46 for Q3 were 18% higher than the prior-year quarter's $0.39 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 64.8%, 200 basis points better than the prior-year quarter. Operating margin was 15.6%, 150 basis points better than the prior-year quarter. Net margin was 6.3%, 70 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $832.4 million. The average EPS estimate is $3.04.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 154 members out of 163 rating the stock outperform, and nine members rating it underperform. Among 59 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 57 give Integra LifeSciences Holdings a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Integra LifeSciences Holdings is outperform, with an average price target of $43.27.
Is Integra LifeSciences Holdings the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Integra LifeSciences Holdings to My Watchlist.